AlphaMark Advisors’s BioDelivery Sciences International, Inc. BDSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-400
Closed -$1K 666
2021
Q4
$1K Hold
400
﹤0.01% 572
2021
Q3
$1K Sell
400
-500
-56% -$1.89K ﹤0.01% 573
2021
Q2
$3K Hold
900
﹤0.01% 505
2021
Q1
$4K Sell
900
-200
-18% -$826 ﹤0.01% 473
2020
Q4
$5K Hold
1,100
﹤0.01% 424
2020
Q3
$4K Hold
1,100
﹤0.01% 460
2020
Q2
$5K Hold
1,100
﹤0.01% 440
2020
Q1
$4K Hold
1,100
﹤0.01% 412
2019
Q4
$7K Hold
1,100
﹤0.01% 381
2019
Q3
$5K Hold
1,100
﹤0.01% 403
2019
Q2
$5K Hold
1,100
﹤0.01% 425
2019
Q1
$6K Hold
1,100
﹤0.01% 391
2018
Q4
$4K Hold
1,100
﹤0.01% 412
2018
Q3
$3K Hold
1,100
﹤0.01% 464
2018
Q2
$3K Hold
1,100
﹤0.01% 476
2018
Q1
$2K Hold
1,100
﹤0.01% 488
2017
Q4
$3K Hold
1,100
﹤0.01% 465
2017
Q3
$3K Hold
1,100
﹤0.01% 462
2017
Q2
$3K Hold
1,100
﹤0.01% 473
2017
Q1
$2K Buy
1,100
+500
+83% +$964 ﹤0.01% 472
2016
Q4
$1K Buy
+600
New +$1.23K ﹤0.01% 454

Other funds holding BDSI

AlphaMark Advisors's BDSI Position: Q1 2022 in Review

AlphaMark Advisors sold out of BioDelivery Sciences International, Inc. (BDSI) in Q1 2022, closing a stake of 400 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in BDSI in Q4 2016 and held it in 21 quarters. The position peaked at $7K in Q4 2019. 2 funds tracked by Wall St. Rank hold BDSI as of Q1 2022.

  • AlphaMark Advisors reported no remaining BioDelivery Sciences International, Inc. position as of Q1 2022 after selling out during the quarter.
  • AlphaMark Advisors sold 400 BioDelivery Sciences International, Inc. shares in Q1 2022, an estimated $1K.
  • AlphaMark Advisors first reported a position in BioDelivery Sciences International, Inc. in Q4 2016 and held it in 21 quarters.
  • AlphaMark Advisors's BioDelivery Sciences International, Inc. position peaked at $7K in Q4 2019.
  • 2 funds tracked by Wall St. Rank held BioDelivery Sciences International, Inc. as of Q1 2022.

Based on AlphaMark Advisors's 13F filing for Q1 2022, filed 2 May 2022.